Abstract:P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase, which is associated with many cancer diseases, and thus being considered as a potential drug target. In this study, three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations were performed to explore the structure-activity relationship of a series of pyrropyrazole PAK4 inhibitors. The statistical parameters of comparative molecular field analysis (CoMFA, Q2 = 0.837, R2 = 0.990, and R2pred = 0.967) and comparative molecular similarity indices analysis (CoMSIA, Q2 = 0.720, R2 = 0.972, and R2pred = 0.946) were obtained from 3D-QSAR model, which exhibited good predictive ability and significant statistical reliability. The binding mode of PAK4 with its inhibitors was obtained through molecular docking study, which indicated that the residues of GLU396, LEU398, LYS350, and ASP458 were important for activity. Molecular mechanics generalized born surface area (MM-GBSA) method was performed to calculate the binding free energy, which indicated that the coulomb, lipophilic and van der Waals (vdW) interactions made major contributions to the binding affinity. Furthermore, through 100 ns MD simulations, we obtained the key amino acid residues and the types of interactions they participated in. Based on the constructed 3D-QSAR model, some novel pyrropyrazole derivatives targeting PAK4 were designed with improved predicted activities. Pharmacokinetic and toxicity predictions of the designed PAK4 inhibitors were obtained by the pkCSM, indicating these compounds had better absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. Above research provided a valuable insight for developing novel and effective pyrropyrazole compounds targeting PAK4.Communicated by Ramaswamy H. SarmaThe 3D-QSAR on pyrropyrazole PAK4 inhibitors was studied for the first time and the constructed 3D-QSAR model exhibited good predictive ability and significant statistical reliability.Molecular docking and molecular dynamics simulations were performed to obtain the binding mechanism, and the binding free energy was calculated by MM-GBSA method.Based on the CoMFA and CoMSIA models, a series of pyrropyrazole derivatives with potential better bioactivities were designed.ADMET properties of the newly designed PAK4 inhibitors were predicted, and these inhibitors exhibited better ADMET properties. three-dimensional quantitative structure-activity relationshipabsorption, distribution, metabolism, excretion, toxicitycomputer-aided drug designcomparative molecular field analysiscomparative molecular similarity indices analysisF-statistic valueshydrogen bond acceptorhydrogen bond donorlimited memory Broyden Fletcher Goldfarb Shannoleave one outmaximum common substructuremolecular dynamicsmolecular mechanics generalized-born surface areanormal pressure temperatureoptimal number of componentspartial least squarecross-validated correlation coefficient; R2, noncross-validated correlation coefficient; R2predictive correlation coefficientroot-mean-square deviationroot mean square errorstandard error of estimatesimple point chargestandard deviation and coefficientvan der WaalseXtended electron distribution.

Insights into the structural requirements of PKCζ inhibitors as potential anti-arthritis agents based on 3D-QSAR, homology modeling and docking approach

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

Exploring the Structure Requirement for PKCθ Inhibitory Activity of Pyridinecarbonitrile Derivatives: an in Silico Analysis.

Target based structural optimization of substituted pyrazolopyrimidine analogues as inhibitor for IRAK4 by 3D-QSAR and molecular simulation

Identify promising IKK-β inhibitors: A docking-based 3D-QSAR study combining molecular design and molecular dynamics simulation

In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives

Computational 3D Modeling-Based Identification of Inhibitors Targeting Cysteine Covalent Bond Catalysts for JAK3 and CYP3A4 Enzymes in the Treatment of Rheumatoid Arthritis

Revealing innovative JAK1 and JAK3 inhibitors: a comprehensive study utilizing QSAR, 3D-Pharmacophore screening, molecular docking, molecular dynamics, and MM/GBSA analyses

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

A structure-based approach to explore novel COX-2 inhibitors using pharmacophore modelling, 3D-QSAR analysis, virtual screening and dynamics simulation study

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Comparative Molecular Field Analysis of Pyrrolidine Inhibitors for Human Cytosolic Phospholipase A2

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

Structural and biochemical insights into the homotypic PB1-PB1 complex between PKCζ and p62

In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation

A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors

Identification of potent CypD inhibitors via pharmacophore based virtual screening, docking and molecular dynamics simulation

Deciphering Cathepsin K inhibitors: a combined QSAR, docking and MD simulation based machine learning approaches for drug design

Discovery of 4-Aminoquinoline-3-carboxamide Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis